Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Development and characterization of a stable eGFP enterovirus 71 for antiviral screening.

Shang B, Deng C, Ye H, Xu W, Yuan Z, Shi PY, Zhang B.

Antiviral Res. 2013 Feb;97(2):198-205. doi: 10.1016/j.antiviral.2012.12.010. Epub 2012 Dec 22.

PMID:
23267829
2.

Development of a stable Gaussia luciferase enterovirus 71 reporter virus.

Xu LL, Shan C, Deng CL, Li XD, Shang BD, Ye HQ, Liu SQ, Yuan ZM, Wang QY, Shi PY, Zhang B.

J Virol Methods. 2015 Jul;219:62-6. doi: 10.1016/j.jviromet.2015.03.020. Epub 2015 Apr 2.

PMID:
25843263
3.

Development and characterization of a stable luciferase dengue virus for high-throughput screening.

Zou G, Xu HY, Qing M, Wang QY, Shi PY.

Antiviral Res. 2011 Jul;91(1):11-9. doi: 10.1016/j.antiviral.2011.05.001. Epub 2011 May 7.

PMID:
21575658
4.

Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone.

Deng C, Li X, Liu S, Xu L, Ye H, Qin CF, Zhang B.

Virol Sin. 2015 Aug;30(4):269-76. doi: 10.1007/s12250-015-3610-7. Epub 2015 Jul 24.

PMID:
26220729
5.

Single-Round Infectious Particle Antiviral Screening Assays for the Japanese Encephalitis Virus.

Lu CY, Hour MJ, Wang CY, Huang SH, Mu WX, Chang YC, Lin CW.

Viruses. 2017 Apr 10;9(4). pii: E76. doi: 10.3390/v9040076.

6.

Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease.

Wang J, Chen X, Wang W, Zhang Y, Yang Z, Jin Y, Ge HM, Li E, Yang G.

J Ethnopharmacol. 2013 May 2;147(1):114-21. doi: 10.1016/j.jep.2013.02.017. Epub 2013 Feb 27.

PMID:
23454684
7.

Identification of luteolin as enterovirus 71 and coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening.

Xu L, Su W, Jin J, Chen J, Li X, Zhang X, Sun M, Sun S, Fan P, An D, Zhang H, Zhang X, Kong W, Ma T, Jiang C.

Viruses. 2014 Jul 17;6(7):2778-95. doi: 10.3390/v6072778.

8.

Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir.

Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT.

J Infect Dis. 2011 Jun 15;203(12):1784-90. doi: 10.1093/infdis/jir174. Epub 2011 May 2.

PMID:
21536800
9.

Inhibition of enterovirus 71 by adenosine analog NITD008.

Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P, Alonso S, Shi PY, Zhang B.

J Virol. 2014 Oct;88(20):11915-23. doi: 10.1128/JVI.01207-14. Epub 2014 Aug 6.

10.

The antiviral effect of 7-hydroxyisoflavone against Enterovirus 71 in vitro.

Wang HQ, Meng S, Li ZR, Peng ZG, Han YX, Guo SS, Cui XL, Li YH, Jiang JD.

J Asian Nat Prod Res. 2013;15(4):382-9. doi: 10.1080/10286020.2013.770737. Epub 2013 Mar 6.

PMID:
23464760
11.

A 3C(pro)-dependent bioluminescence imaging assay for in vivo evaluation of anti-enterovirus 71 agents.

Guo Z, Zhong X, Lin L, Wu S, Wang T, Chen Y, Zhai X, Wang Y, Wu H, Tong L, Han Y, Pan B, Peng Y, Si X, Zhang F, Zhao W, Zhong Z.

Antiviral Res. 2014 Jan;101:82-92. doi: 10.1016/j.antiviral.2013.11.002. Epub 2013 Nov 18.

PMID:
24263113
12.

[Study on the association of hand, foot and mouth disease and enterovirus 71/CA16 among children in Beijing, 2007].

Zhu RN, Qian Y, Deng J, Xing JF, Zhao LQ, Wang F, Liao B, Ren XX, Li Y, Zhang Q, Li J.

Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct;28(10):1004-8. Chinese.

PMID:
18399150
13.

Antiviral activity of Paulownia tomentosa against enterovirus 71 of hand, foot, and mouth disease.

Ji P, Chen C, Hu Y, Zhan Z, Pan W, Li R, Li E, Ge HM, Yang G.

Biol Pharm Bull. 2015;38(1):1-6. doi: 10.1248/bpb.b14-00357.

14.

Identification of Positively Charged Residues in Enterovirus 71 Capsid Protein VP1 Essential for Production of Infectious Particles.

Yuan S, Li G, Wang Y, Gao Q, Wang Y, Cui R, Altmeyer R, Zou G.

J Virol. 2015 Oct 28;90(2):741-52. doi: 10.1128/JVI.02482-15.

15.

Development of Neutralization Assay Using an eGFP Chikungunya Virus.

Deng CL, Liu SQ, Zhou DG, Xu LL, Li XD, Zhang PT, Li PH, Ye HQ, Wei HP, Yuan ZM, Qin CF, Zhang B.

Viruses. 2016 Jun 28;8(7). pii: E181. doi: 10.3390/v8070181.

16.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.

Virology. 2005 Feb 5;332(1):20-7.

17.

Pyrrolidine dithiocarbamate inhibits enterovirus 71 replication by down-regulating ubiquitin-proteasome system.

Lin L, Qin Y, Wu H, Chen Y, Wu S, Si X, Wang H, Wang T, Zhong X, Zhai X, Tong L, Pan B, Zhang F, Zhong Z, Wang Y, Zhao W.

Virus Res. 2015 Jan 2;195:207-16. doi: 10.1016/j.virusres.2014.10.012. Epub 2014 Oct 23.

PMID:
25456405
18.

Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection.

Zhang W, Tao J, Yang X, Yang Z, Zhang L, Liu H, Wu K, Wu J.

Biochem Biophys Res Commun. 2014 Jul 4;449(3):307-12. doi: 10.1016/j.bbrc.2014.05.019. Epub 2014 May 15.

PMID:
24845570
19.

Potent inhibition of human enterovirus 71 replication by type I interferon subtypes.

Yi L, He Y, Chen Y, Kung HF, He ML.

Antivir Ther. 2011;16(1):51-8. doi: 10.3851/IMP1720.

PMID:
21311108
20.

Mapping genetic determinants of the cell-culture growth phenotype of enterovirus 71.

Phuektes P, Chua BH, Sanders S, Bek EJ, Kok CC, McMinn PC.

J Gen Virol. 2011 Jun;92(Pt 6):1380-90. doi: 10.1099/vir.0.029371-0. Epub 2011 Feb 23.

Supplemental Content

Support Center